Capelletto Enrica, Bironzo Paolo, Denis Louis, Koustenis Andrew, Bungaro Maristella, Novello Silvia
Department of Oncology, University of Turin, Italy.
Verastem Oncology - Chief Medical Officer, Needham, MA, USA.
Future Oncol. 2022 May;18(16):1907-1915. doi: 10.2217/fon-2021-1582. Epub 2022 Mar 14.
mutations occur in approximately 30% of lung adenocarcinomas, mainly in codon 12 (83% of cases), p.G12C being the prevalent one (40%), followed by p.G12V and p.G12D (22 and 16%, respectively). Treatment options for advanced mutant non-small-cell lung cancer (-MT NSCLC) are limited to chemotherapy and immune checkpoint inhibitors (CPIs). However, clinical trials exploring specific targeted agents are expected to change the treatment landscape of this disease. Here, we describe the design and scientific rationale of the randomized, phase II, open label, RAMP-202 study, which will evaluate the efficacy and safety of VS-6766 versus VS-6766 in combination with defactinib in advanced -MT NSCLC patients after failure of prior platinum-based chemotherapy and CPI.
约30%的肺腺癌会发生突变，主要发生在密码子12（83%的病例），其中p.G12C最为常见（40%），其次是p.G12V和p.G12D（分别为22%和16%）。晚期突变型非小细胞肺癌（-MT NSCLC）的治疗选择仅限于化疗和免疫检查点抑制剂（CPI）。然而，探索特定靶向药物的临床试验有望改变这种疾病的治疗格局。在此，我们描述了随机、II期、开放标签的RAMP-202研究的设计和科学原理，该研究将评估VS-6766单药与VS-6766联合defactinib在先前铂类化疗和CPI治疗失败后的晚期-MT NSCLC患者中的疗效和安全性。
